Sword & Shield Pharma Ltd.

Sword & Shield Pharma Ltd. Regd. Office: 311, Rajkamal Plaza-B. 4/B, Sattar Taluka Society, Opp Old High Court. Ahmedabad-38 14. Gujarat, INDIA. Telefax 79-2754329 E-mail sspl24@yahoo com Works : 31/M, G ID C, Phase Ill, Chhatral-382 729, Dis!. Gandhinagar (N.Gujarat) INDIA. Phone (2764) 233322 Website www.swordnshieldpharma.com Date: November 14, 215. To, BSE Limited Ph iroze jeejeebhoy Towers, Dnlal Street, Mumbai - 4 1. Dear Si r, Sub : Sub mission of Financial Results for the Qu arter and Half year September 3,215 in terms of Clause 41 of the Listing Agreement. Ref: Sword & Shield Phanna Limited. (Security ldjcode: SWORDNSH/531637) Pursuant to Clause 11 of the Li sting Agreement, we hereby inform you th at th e Board of Directors of th e Company, in their meeting held on November 14, 215, at th e Registered Office of th e Company, have considered fo ll owin g matters: 1. The Board of Directors have inter alia consid ered, approved and ta ken on record the unaudited fina ncial res ults of th e Company along with Limi ted Revi ew report for the Quarter a nd Half yea r end ed on Se pte mb er 3, 215. The ste1te ment of Un audited r:in anci al results of th e Company along with the Limi te d l{eview l{eport submitted by the Statutory Auditors of th e Company has been attac hed herewith. 1\indly wke the sa me on yo ur reco rd and obli ge us. Ma naging Director DIN: 1877446

To, The Board of Directors, Sword & Shield Pharma Limited. B. K. PATEL & CO Chartered Accountants 31, 'SAMRUDDHI', Opp. Old High Court, Navjivan P.O., AHMEDABAD- 38 14. Gujarat. PHONES : 79-2754 4927, 2754 1151. FAX - 79-2754 1151 Email : bkpatelandco@gmail.com Limited Review Report We have reviewed the accompanying statement of unaudited financial results of Sword & Shield Pharma Limited for the period September 3, 215 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 24, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Issuer's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement. For, B. K. PATEL & CO Chartered Accountants FRN: 112647W November 14,215 Ahmedabad Part er Membership No. : 39919

SWORD AND SHIELD PHARMA LTD CIN : L24231G)1995PLC2489 Rcg1stered Office: 311, Rajkamal Plaza - B, 4 /B, Sattar Taluka Societ y, Opp. Old High Court, Ahmeda ba d - 38 14. Wehsite: www.swordnshieldpharma.com STAT MEN T OF UNAUDITED FINAN CIAL RESUI,TS FOR THE QUARTE!l M/ D 11 8 1 F l'ea!l EI':/QI;D SEeiEr1BER 3 2Ql5 [Amount in (Rs.)] Corresponding 3 Year to date figures Year to date figures Previous 3 months 3 months months in the for current period for previous pe riod previous year ( dd-mm-yyyy) Previous accounting year A Date of start of reporting quarter 1-7-215 1-4 215 1-7-214 1-4-215 1-4-214 1-4-214 8 Date of end of reporting quarter 3-9-215 3-6-215 3-9-214 3-9-215 3-9-214 31 3 215 c Whether results are audited or unaudited Unaud1ted Unaudited Unaudtted Unaudited Unaudited Audited Nature of report standalone or consol1dated Standalone Standalone Standalone Standalone Standalone Standalone Part I 1 Revenue From Operations All the fileds are mandatory in this sheet 2 Expenses Net sales or Revenue from OQerations. -5113. 21865. -5113. 7686826. 1225461. Other OQerating revenues...... Total Revenue from operations (net) ooool -5113. 21865.1-5 113. 7686826.1 1225461. (a) Cost of matenals consumed. 534639. 184742. 534639. 33 774. 5794522. (b) Purchases of stock-in-trade...... (c) Changes 1 invent ones of f1nished goods work-m-qrogress and stock-in-trade.. 228185.. 29392. 49951. (d) EmQIOee benefit exqense 56772. 569. 925998. 113672. 17648. 3943468. (c) DeQreciation and amortisation exqense 427121. 422478. 91247. 849599. 1814897. 3619876. (f) Other Expenses 1 OTHER EXPENSES 6858. 67148. 26163. 738657. 43765. 1671765. Total other exqenses 6858. 6714. 26163. 738657. 43765. 1671765. Total expenses 16271. 2196265. 3621125. 3258967. 762951. 1S529132. 3 Profit (loss) from operations before other income, finance costs and exceptional items -16271. 221378. -15136. -32648. 83875. -3274531. 4 Other income 81. 81.. 162. 1. 398934. 5 Profit (loss) from ordinary activates before finance costs and e)(ceptional items -25271. -1391378. 15136. -16448. 93875. -2875S97. 6 Finance costs...... 7 Prof1t (loss) from ordinary activities aher f1nance costs but before e)(ceptional1tems -25271. -1391378. 15136. 16448. 93875. 2875597. 8 hceqt1onal1tems 482236... 482236.. -22394. 9 Profit (loss) from ordinary activities before ta)( 229S3S.OOO -1391378. -1S136. -1161844. 93875. -377991. 1 Ta)( hqense -13198. 13546. -351483. -262526. 2188. -714981. 11 Net prof1t (loss) from ordinary activities after ta)( 361515. -126832. -1161577. -899318. 7267. -23631. 12 Extraordinar 1te ms...... 13 Net profit (loss) for the period 361515. -126832. -1161577. -899318. 7267. -23631. 14 Share of profit (loss) of associates 15 Profit {loss) of minority interest 16 Net Profit (loss) after taxes minority interest and share of profit (loss) of associates 361515. -126832. 1161577. -899318. 7267. -23631. 17 Details of equity share capital Paid-up equ1ty share cap1tal 4661917. 4661917. 4661917. 4661917. 4661917. 4661917. Face value of equity share cap tal 1. 1. 1. 1. 1. 1. 18 Reserves excluding revaluation reserve -47818349. -47818349. -45455339. -4 7818349. -45455339. -47818349. 19 Earnings per share i Earnings per share Pefore extraordinary items Bas c earn1ngs per share before e)(traordinary items.78 -.27.249 15 Diluted earn ngs per share before extraordinary Items O.D78-27 -.249 :f,t 15.57 ;, Earnings per share after extraordinary items If... / ""'4"., Bas1c earn1ngs per share a her extraordinary items.78 -. 27 -.249 1. f -.193 ' -' 4HMEDABAD 1:.---- & -.57 Diluted earn1ngs per share after extraordinary items.78 -.27 -.249... -.193.57. -, _., - tiliji.57

SWORD AND SHIELD PHARMA LTD CIN: L24231Gfl995PLC2489 Registered Office. J II, Rajk.unal Plua B. 4/B. Sattar Taluka Socict), Opp. Old High Court, Ahmedabad 38 14. Wehite: www.swordnshieldphanna.com STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SE PTEMBER 3.215 Amount in 3 months Prev1ous 3 months Corresponding 3 months in the prevtous year Year to date figures for current period Year to date figures for previous period Previous accounting year 934%.%.%.%.%.%.%.%.% 34 34 34 34 34 34 1.% 1.% 1.% 1.% 1.% 1.% a% of the total share ca 6.6 ending at the begmning of the quarter Recetved dunng the quarter Disposed of during the quarter Remam1 I Notes: The above results for the Quarter and Half year on September 3, 215 were revtwed by the Audtt Committee and then approved by the Board of Directors at thetr meet eng held on November 14, 215 The Statutory Audttor of the Company have carried out a "Limited Revtew" of the above results as per Clause 41 of the Ust ng Agreement. Ftgures of the prevtous reporttng penod have been regrouped and or reclasstfted wherever necessary to correspond w1th the fcgures of the current report1ng penod The Company has only segment of Act1v1ty. Date : November 14, 215 Place: Ahmedabad Mr. Pravinbhai Patel Managing Director DIN: 1877446

SWORD AND SHIELD PHARMA L TO CIN: L24231G)1995PLC249 Registered Office: 311, Rajkamal Plaza- B, 4fB, Sattar Taluka Society, Opp. Old High Court, Ahmedabad - 38 14. Website: www.swordnsbieldpharma.com 1 2 3 4 5 6 1 (i) (il) (ill) (iv) (v) (vi) 2 STATEMENT OF ASSETS AND LIABILITI ES FOR THE HALF YEAR ENDED SEPTEMBER 3.215.. (Amount in (Rs )] Half year Year Date of start of reporting quarter 1-4-215 1-4-214 Date of en d of reporting qua rter 3-9-215 31-3-215 Whether results are audited or unaudited Unaudited Audited Nature of report standa lone or consolidated Standalone Standalone Equity and liabilities Sh areholders' funds Share capital 4661917. 4661917. Reserves and surplus -48717666. -47818349. Money received agai nst share warrants.. Total shareholders' funds -298496. -1199179. Share application money pending allotment.. Deferred government grants.. Minority Interest.. Non-current liabilities Long-term borrowings 65575. 65575. Deferred tax liabilities (net).. Foreign currency monetary item translation difference liability account.. Other long-term liabilities.. Long-term provisions.. Total non-current liabilities 65575. 65575. Current liabilities Short-term borrowings.. Trade payables 153674. 576669. Other cu rren t lia bilities 4387978. 6163714. Short-term provisions 6577. 1177. Total current liabilities 5898229. 67556. Total equity and liabilities 1357233. 1218881. Assets Non-current assets Fi xed assets Tangible assets 667 1441. Produc1ng properties. (52l4.QOO.. Intangible assets.. Preproducing properties.. Tangible assets cap ital work-in-progress.. Intangible assets under development or work-in-progress.. Total fixed asse ts 6671441. 752 14. Non-current investments.. Deferred tax assets (net) 1286885. 124359. Foreign currency monetary item transla tion difference asset account Long-term loans and advanc es. Other non-c urrent assets.. Total non-curren t assets 1286885. 124359. Current asse ts Current investments.. Invent ones. 534639. Trade receivables 748778. 147672. Cash and bank balances 597212. 594438. Short-term loans and advances 152917. 957685. Other cu rren t assets.. Total curren t assets 239897. 3563482. Total asset s 1357233. 1218881. Date : Novemhc1 1. 21S I' lace: i\hmedab.jrl f 13oMd of Directo rs Mr. Pravinbhai Patel Managing Di1 ector DIN: 1 87746